Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SMPDL3B CRISPR Activation Plasmid (h): sc-404724-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SMPDL3B CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- SMPDL3B CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SMPDL3B CRISPR Activation Plasmid (h) and SMPDL3B CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SMPDL3B transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SMPDL3B Antibody (H-3): sc-137113
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SMPDL3B CRISPR Activation Plasmid (h) | sc-404724-ACT | 20 µg | $397.00 |
Human SMPDL3B (sphingomyelin phosphodiesterase acid-like 3B) encodes a GPI-anchored membrane-associated protein with homology to sphingomyelinase-related enzymes and is implicated in regulating sphingolipid and membrane lipid homeostasis. By influencing lipid composition and microdomain organization, SMPDL3B can modulate receptor signaling, vesicle trafficking, and innate immune signaling outputs in myeloid and other cell types. Altered SMPDL3B expression has been linked in the literature to immune and inflammatory phenotypes and has been investigated in contexts such as kidney and metabolic disease biology where lipid remodeling and immune signaling intersect. These features make SMPDL3B a useful target for studying membrane-proximal signaling mechanisms and lipid-driven regulation of cellular activation states.
SMPDL3B CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SMPDL3B expression without altering the underlying DNA sequence.
SMPDL3B CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SMPDL3B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SMPDL3B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SMPDL3B expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SMPDL3B locus and enabling the study of SMPDL3B-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SMPDL3B pathway restoration in tumor cells with silenced or reduced SMPDL3B expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.